tailieunhanh - Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

Chk1 inhibitors are currently in clinical trials as putative potentiators of cytotoxic chemotherapy drugs. Chk1 inhibitors may exhibit single agent anti-tumor activity in cancers with underlying DNA repair, DNA damage response or DNA replication defects. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN